Evidence map›Paper›PMID 33441685›Full record

ArticleScientific reports2021

Enhanced oncolytic adenoviral production by downregulation of death-domain associated protein and overexpression of precursor terminal protein.

Jihyun Lee, Geun-Hyeok Oh, Jeong A Hong, Soojin Choi, Hye Jin Choi, Jae J Song

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Jihyun LeeInstitute for Cancer Research, Yonsei University College of Medicine, Seoul, Republic of Korea.
Geun-Hyeok OhInstitute for Cancer Research, Yonsei University College of Medicine, Seoul, Republic of Korea.
Jeong A HongInstitute for Cancer Research, Yonsei University College of Medicine, Seoul, Republic of Korea.
Soojin ChoiInstitute for Cancer Research, Yonsei University College of Medicine, Seoul, Republic of Korea.
Hye Jin ChoiDepartment of Internal Medicine, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, Republic of Korea. choihj@yuhs.ac.
Jae J SongInstitute for Cancer Research, Yonsei University College of Medicine, Seoul, Republic of Korea. jjs109@yuhs.ac.
Yonsei University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Adequate viral replication in tumor cells is the key to improving the anti-cancer effects of oncolytic adenovirus therapy. In this study, we introduced short hairpin RNAs against death-domain associated protein (Daxx), a repressor of adenoviral replication, and precursor terminal protein (pTP), an initiator of adenoviral genome replication, into adenoviral constructs to determine their contributions to viral replication. Both Daxx downregulation and pTP overexpression increased viral production in variety of human cancer cell lines, and the enhanced production of virus progeny resulted in more cell lysis in vitro, and tumor regression in vivo. We confirmed that increased virus production by Daxx silencing, or pTP overexpression, occurred using different mechanisms by analyzing levels of adenoviral protein expression and virus production. Specifically, Daxx downregulation promoted both virus replication and oncolysis in a consecutive manner by optimizing IVa2-based packaging efficiency, while pTP overexpression by increasing both infectious and total virus particles but their contribution to increased viral production may have been damaged to some extent by their another contribution to apoptosis and autophagy. Therefore, introducing both Daxx shRNA and pTP in virotherapy may be a suitable strategy to increase apoptotic tumor-cell death and to overcome poor viral replication, leading to meaningful reductions in tumor growth in vivo.

Indexed as

AdenoviridaeAdenovirus E1A ProteinsAdenovirus E2 ProteinsCell Line, TumorCo-Repressor ProteinsHumansMolecular ChaperonesOncolytic VirotherapyOncolytic VirusesRNA, Small InterferingViral ProteinsVirus ReplicationAdenovirus E1A ProteinsAdenovirus E2 ProteinsCo-Repressor ProteinsDAXX protein, humanMolecular ChaperonesRNA, Small InterferingViral Proteins

Identifiers

PMID33441685
PMCPMC7807022
OpenAlexW3119842435

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.